HOME >> BIOLOGY >> NEWS
Acamprosate: potential medication for treating alcoholism

  • Acamprosate is a medication used in Europe and elsewhere to prevent relapse in alcoholics.
  • New findings, in conjunction with previous research, indicate that acamprosate should be safe to take when people are drinking, and should not make them want to drink more or behave differently over and above the effects of alcohol alone.

As scientists and clinicians learn more about the changes in brain chemistry that chronic alcohol use can cause, the pharmacotherapy of alcoholism has become increasingly relevant for the treatment of alcohol craving, abstinence, and relapse. A study in the July issue of Alcoholism: Clinical & Experimental Research examines the effects of acamprosate (calcium acetyl homotaurinate), a medication used in Europe and elsewhere to prevent relapse in alcoholics, and currently under review for use by the U.S. Food and Drug Administration. The study's findings, in conjunction with previous research, indicate that acamprosate should be safe to take when people are drinking, and should not make them want to drink more or behave differently over and above the effects of alcohol alone.

"To our knowledge, this is the first published report that examines potential interactions between acamprosate and alcohol in humans," said Elisabeth J. Houtsmuller, assistant professor of behavioral biology at Johns Hopkins University School of Medicine and corresponding author for the study. "Other studies have shown that acamprosate helps people abstain from drinking, and our study examined what may underlie this. Because acamprosate acts on a neurotransmitter system the glutamate system that alcohol also has many effects on, we thought it was possible that acamprosate might change some of alcohol's effects, and this might be part of why it helps people to abstain. We therefore examined whether acamprosate alters the way alcohol makes people feel."

The findings suggest that acamprosate does not'"/>


14-Jul-2004


Page: 1 2 3 4

Related biology news :

1. Award winning researchers reveal potential new role for Glivec
2. Evidence builds for potential new cancer drug target
3. Scientists discover potential new way to control drug-resistant bacteria
4. Tiny molecules have big potential as cancer drugs, Stanford researcher believes
5. OneWorld Health compiles comprehensive state of infectious diarrhea treatments, potential solutions
6. Managing occupational exposures to potential bioterrorist agents
7. Location of potential familial lung cancer gene discovered
8. Common chemicals morphing into potential toxins in Arctic
9. Yale researchers discover new potential asthma therapeutic targets related to parasites and insects
10. Researchers identify two potential protein targets for new drug therapies for pancreatic cancer
11. New screening method turns up potential compound for treating anthrax

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/7/2019)... ... May 07, 2019 , ... ... Long Beach Convention and Entertainment Center from May 15- 17. At booth #226, ... solutions. These include flexible software, biometric hardware, mobile apps, specialized industry solutions, advanced ...
(Date:5/2/2019)... ... April 30, 2019 , ... Global ... announces today that Holotype HLA and other Omixon products will be featured in ... Immunogenetics (EFI) in Lisbon, Portugal. Among the major scientific events, Omixon’s ...
(Date:5/2/2019)... (PRWEB) , ... May 01, 2019 , ... ... Board of Directors has appointed John Rakow, the Company’s General Counsel, as Interim ... Richman and Zac Apte, are currently on administrative leave. There will also be ...
Breaking Biology News(10 mins):
(Date:4/9/2019)... ... ... The American Society of Gene & Cell Therapy (ASGCT) is excited to ... the presidential line of succession, at the 22nd Annual Meeting . Members of ... three-year term (2019-2021). , All five incoming members of the ASGCT Board of ...
(Date:4/8/2019)... , ... April 08, 2019 , ... US Capital ... a $15 million preferred equity investment in the privately held pharmaceutical company, S1 Biopharma ... drug, Lorexys, is targeted at female hypoactive sexual dysfunction disorder and is ready to ...
(Date:4/4/2019)... ... April 02, 2019 , ... Biomeme, Inc. , a ... latest field-ready solution for performing PCR, RT-PCR, qPCR, and Isothermal tests called ... Rosland Franklin, an English chemist and X-ray crystallographer who made significant contributions to ...
(Date:3/29/2019)... ... March 28, 2019 , ... Specific Diagnostics announced today ... with a second stage of funding for Specific’s Reveal™ rapid antibiotic susceptibility test ... of the $1.7 million already awarded by CARB-X. The additional $1.7M will enable ...
Breaking Biology Technology:
Cached News: